Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3521 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-712 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
filingDate |
2006-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2017-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-101789603-B1 |
titleOfInvention |
Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
abstract |
Disclosed are methods and compositions for controlling the expression of these receptors using compounds that modulate splicing of pre-mRNAs encoding TNF receptors (TNFR1 and TNFR2) and other receptors belonging to the TNFR superfamily. In particular, these compounds produce a soluble form of the receptor that acts as an antagonist which causes the elimination of the transmembrane domain of the receptor and reduces the activity of TNF-a activity or related ligands. Reducing TNF-a activity provides a method of treating and ameliorating an inflammatory disease or condition associated with TNF-a activity. Likewise, diseases associated with other ligands can be treated in a similar manner. In particular, the compound of the present invention is a splice-splicing switching oligomer (SSO) which is a small molecule stable in vivo, is hybridized to RNA in a sequence-specific manner, and is not degraded by an antigen H . |
priorityDate |
2005-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |